GleamWall
中文EN

NEUP Neuphoria Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1191070 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY47.5%
TTM EPS YoY127.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-27.6%
ROA-18.3%
ROIC (approx.)-568.0%
Asset turnover—

Leverage & solvency

Liabilities / assets13.4%
Debt / equity0.00x
Current ratio18.05x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.95x
Accruals ratio17.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30
Income statement
Revenue$1.17M$15.65M
R&D expense—$9.01M
SG&A expense$7.44M$7.77M
Operating income-$16.45M-$1.13M
Pretax income-$13.59M-$837,998
Income tax-$139,173-$468,366
Net income-$13.45M-$369,632
EBITDA-$15.79M-$466,201
EPS (basic)-3.06-0.23
EPS (diluted)-3.06-0.23
Weighted avg. shares (diluted)4.40M1.62M
Balance sheet
Cash & equivalents$19.87M$14.29M
Receivables$813,431$11,948
Current assets$21.07M$15.04M
PP&E, net—$2,771
Goodwill$3.50M$8.64M
Intangibles$4.14M$4.80M
Total assets$28.71M$28.59M
Current liabilities$756,581$4.22M
Total liabilities$4.11M$9.59M
Shareholders' equity$24.60M$19.00M
Shares outstanding5.41M1.98M
Cash flow statement
Operating cash flow-$12.35M$77,229
Financing cash flow$17.92M$1.53M
Depreciation & amortization$662,955$662,890
Stock-based compensation$351,600$163,772

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.